View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 7, 2022

Enlivex to initiate Phase I/II peritoneal metastases cell therapy trial

The clinical trial of Allocetra will commence with two cohorts of intra-patient and intra-cohort dose escalation.

Enlivex Therapeutics has received the Israeli Ministry of Health (MOH) authorisation to initiate a Phase I/II clinical trial of its cell therapy Allocetra along with chemotherapy in patients with peritoneal metastases arising from solid cancer.

The company-sponsored, open-label dose escalation and expansion trial of the universal, off-the-shelf therapy is expected to enroll a total of nearly 12 patients across four cohorts.

It will assess the potential preliminary efficacy and safety of Allocetra and SOC chemotherapy combination in peritoneal metastases patients.

For determining the maximum feasible dose (MFD) of Allocetra, the trial will begin with two cohorts of intra-patient and intra-cohort dose escalation.

This will be followed by another two cohorts to compare the therapy administration at the selected dose either before or after administration of SOC through a pressurised intraperitoneal aerosol chemotherapy procedure (PIPAC). 

Enlivex Therapeutics Medical vice-president Einat Galamidi said: “Our preclinical studies suggest Allocetra may enhance the efficacy of a broad range of therapeutic agents by weakening tumour defense mechanisms through a novel mechanism of action that drives macrophage populations towards a more anti-cancer state.

“We look forward to beginning the clinical evaluation of this hypothesis through both this chemotherapy combination study and an additional planned solid tumour study that will evaluate Allocetra combined with a checkpoint inhibitor.”

Every six weeks, the trial subjects will receive intraperitoneally delivered Allocetra and SOC chemotherapy administered through the PIPAC technique.

As per the treatment plan of the oncologist, they will also receive systemic chemotherapy.

Number and severity of Allocetra-related and serious adverse events during the 16-week period is the primary endpoint of the trial.

Efficacy assessments, such as best overall response rate (ORR), overall survival and progression-free survival are included as secondary endpoints.

Evaluation of variations from baseline in macrophage and immune cell characteristics in peritoneal fluid and tissues will be considered as an exploratory endpoint.

Enlivex plans to initiate the Phase I/II trial of Allocetra and chemotherapy combination in the third quarter of this year and also expects to initiate a Phase I/II trial of the therapy along with an immune checkpoint inhibitor late this year.

In August last year, Enlivex announced a Phase IIb trial of Allocetra in severe and critical Covid-19 patients with acute respiratory distressed syndrome.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena